Login / Signup

An evaluation of ivosidenib for the treatment of IDH1 -mutant cholangiocarcinoma.

Sri Harsha TellaAmit Mahipal
Published in: Expert opinion on pharmacotherapy (2022)
-mutant cholangiocarcinoma that progressed on first-line chemotherapy given its excellent tolerability and median OS benefit. However, a few questions remain unanswered - sequencing of targeted therapies, benefits of combining targeted therapy with systemic chemotherapy or with other treatment modalities, such as immunotherapy and localized therapies.
Keyphrases
  • locally advanced
  • squamous cell carcinoma
  • wild type
  • open label
  • radiation therapy
  • combination therapy
  • rectal cancer